Poolbeg Pharma's Jeremy Skillington and Brad Pryde, the co-founder and COO of OneThree join Proactive London to talk about their artificial Intelligence discovery deal signed with OneThree Biotech.
The first time human challenge trial data will be analysed using AI to gain valuable insight and identify new treatments for infectious diseases.
Poolbeg Pharma is a clinical stage infectious disease pharmaceutical company with a capital light clinical model, has signed an agreement with OneThree Biotech, Inc. a biology-driven artificial intelligence (‘AI’) company, to identify new drug targets and treatments for Respiratory Syncytial Virus (‘RSV’).